Skip to Main Content

Following a two-year inquiry, the European Ombudsman has recommended the European Medicines Agency take several steps to ensure that private talks with drug makers about marketing applications do not influence approval decisions.

At issue are pre-submission discussions that occur between companies and the regulator, which Ombudsman Emily O’Reilly probed over concerns such talks run the risk of creating a perception of bias or that companies may somehow exert pressure on agency officials to view applications favorably.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED